The results showed that Apl-1 exhibited potent cytotoxicity against leukemia cancer cells (Molt 4 and K562 cells with IC50 of 0.12 ± 0.002 and 0.54 ± 0.085 μM) and androgen-independent prostate cancer cells (PC-3 and Du145 cells with IC50 of 0.58 ± 0.109 and 0.33 ± 0.042 μM). Here, ADI1 is linked to prostate cancer.